Discovery of Raltegravir, a potent, selective orally bioavailable HIV-integrase inhibitor for the treatment of HIV-AIDS infection

Human immunodeficiency virus type-1 (HIV-1) integrase is one of the three virally encoded enzymes required for replication and therefore a rational target for chemotherapeutic intervention in the treatment of HIV-1 infection. We report here the discovery of Raltegravir, the first HIV-integrase inhib...

Celý popis

Uložené v:

Podrobná bibliografia
Vydané v:	Journal of medicinal chemistry Ročník 51; číslo 18; s. 5843 - 5855
Hlavní autori:	Summa, Vincenzo, Petrocchi, Alessia, Bonelli, Fabio, Crescenzi, Benedetta, Donghi, Monica, Ferrara, Marco, Fiore, Fabrizio, Gardelli, Cristina, Paz, Odalys Gonzalez, Hazuda, Daria J., Jones, Philip, Kinzel, Olaf, Laufer, Ralph, Monteagudo, Edith, Muraglia, Ester, Nizi, Emanuela, Orvieto, Federica, Pace, Paola, Pescatore, Giovanna, Scarpelli, Rita, Stillmock, Kara, Witmer, Marc V., Rowley, Michael
Médium:	Journal Article
Jazyk:	English
Vydavateľské údaje:	WASHINGTON Amer Chemical Soc 25.09.2008
Predmet:	Administration, Oral Area Under Curve Biological Availability Chemistry, Medicinal Half-Life HIV Infections - drug therapy HIV Integrase Inhibitors - administration & dosage HIV Integrase Inhibitors - pharmacokinetics HIV Integrase Inhibitors - pharmacology HIV Integrase Inhibitors - therapeutic use Humans Life Sciences & Biomedicine Magnetic Resonance Spectroscopy Mass Spectrometry Pharmacology & Pharmacy Pyrrolidinones - administration & dosage Pyrrolidinones - pharmacokinetics Pyrrolidinones - pharmacology Pyrrolidinones - therapeutic use Raltegravir Potassium Science & Technology CELLS DESIGN DEPENDENT RNA-POLYMERASE REPLICATION 4,5-DIHYDROXYPYRIMIDINE ACIDS
ISSN:	0022-2623, 1520-4804, 1520-4804
On-line prístup:	Zistit podrobnosti o prístupe
Tagy:	Pridať tag Žiadne tagy, Buďte prvý, kto otaguje tento záznam!

Buďte prvý, kto okomentuje tento záznam!